First-line Treatment of Metastatic Disease

Sep 16, 2017 by in HEMATOLOGY Comments Off on First-line Treatment of Metastatic Disease

More than 50% of patients with advanced urothelial carcinoma are not eligible for the standard treatment with cisplatin-based chemotherapy. In general, cisplatin-ineligible patients with metastatic urothelial cancer experience poor outcomes…

read more

First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients

Sep 16, 2017 by in HEMATOLOGY Comments Off on First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients

Metastatic urothelial carcinoma is primarily a disease of the elderly, with a median overall survival of approximately 15 months. Cisplatin-based combination chemotherapy is standard first-line treatment for eligible patients, with…

read more

Bladder Preservation Strategies

Sep 16, 2017 by in HEMATOLOGY Comments Off on Bladder Preservation Strategies

Although cystectomy remains the standard for treatment of muscle-invasive bladder cancer in the United States, there exist potentially curative alternatives for a selected subset of these patients in organ preservation…

read more
Get Clinical Tree app for offline access